Pharmaceuticals
Pharma - Formulators
from 2,230 today
Glenmark Pharmaceuticals' Q1FY27 revenue outperformed estimates, driven by strong growth across India, the US, and emerging markets, although EBITDA and profits lagged expectations due to weakened gross and EBITDA margins. We maintain our HOLD rating and target price of INR 2,100.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
